Montreal Researchers Uncover New Targets for Pediatric Cancer Treatments

Researchers at CHU Sainte-Justine in Montreal have made significant strides in the fight against pediatric cancer by identifying new targets on cancer cell surfaces. Their groundbreaking work could lead to the development of ultra-targeted immunotherapies, offering fresh hope for children diagnosed with various forms of cancer.

The research team developed a sophisticated computer tool, ProteoFusioNEO, which facilitates the analysis of transcriptomes from over 5,100 children with different types of pediatric cancers, along with 935 cell lines. This analysis revealed the presence of neoantigens—small fragments of abnormal proteins produced by gene fusions—on the surfaces of cancer cells.

Understanding Pediatric Cancer’s Unique Genetic Signature

According to Isabelle Sirois, head of the Proteomics and Immunopeptidomics Platform at CHU Sainte-Justine, pediatric cancers exhibit a distinct genetic signature characterized by fusion genes. These genes result from the combination of genetic material, creating “super genes” that can independently induce cancer. This unique signature provides a promising avenue for identifying new therapeutic targets specific to cancer cells.

The potential for ultra-targeted immunotherapies lies in their ability to precisely attack cancer cells while sparing healthy cells. For this to occur, the immune system must be presented with targets exclusive to diseased cells. The approach of immunopeptidomics plays a crucial role in this process by identifying small protein fragments on cell surfaces, which act as signals for the immune system.

Mass spectrometry and the computational tools used in this study, published in the journal iScience, have successfully predicted and confirmed that neoantigens resulting from gene fusions are displayed on the surfaces of cancer cells. “The cell has to get rid of its protein waste continuously,” Sirois explained. “This waste is loaded onto molecules that carry it to the cell surface, signaling the immune system.”

New Treatment Possibilities on the Horizon

Not all neoantigens possess the same therapeutic potential, but some stand out due to their specificity and distinctiveness from normal body proteins. These characteristics position them as prime targets for precision immunotherapies. The discoveries made by the CHU Sainte-Justine team open the door for developing messenger RNA vaccines, which would teach the immune system to recognize these neoantigens.

“We’re going to do exactly the same thing we did with messenger RNA vaccines during COVID,” Sirois noted. “But instead of providing a virus sequence, we’re introducing sequences of molecular flags that will instruct the immune system to eliminate tumor cells.” This innovative technique not only identifies targets but also guides the development of new immunotherapies tailored to individual patients.

Some immunotherapies may require numerous targets, while others may function effectively with fewer. This flexibility represents a significant advancement compared to traditional chemotherapy, which has been the standard for over 70 years in treating pediatric cancers. “There are really new treatment possibilities,” Sirois concluded, emphasizing the promising future of this research.

The findings from this study could reshape the landscape of pediatric cancer treatment, offering hope to families and children facing these challenging diagnoses. As research continues, the potential for innovative therapies grows, paving the way for a future where cancer can be targeted more effectively and safely.

This report by The Canadian Press was first published on February 15, 2026.